Pharmaceutical composition containing ivabradine and ranolazine

A composition, the technology of ranolazine, applied in the field of medicine, can solve the problems of difficulty in obtaining satisfactory curative effect on angina pectoris, aggravated headache, reflex tachycardia, etc., and achieve the effect of improving myocardial energy utilization, relieving harm, and thoroughly curative effect
CN101780091BActive Publication Date: 2011-11-30LUNAN PHARMA GROUP CORPORATION
1 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
LUNAN PHARMA GROUP CORPORATION
Publication Date
2011-11-30

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition containing active ingredients ivabradine or a pharmacologically acceptable salt thereof and ranolazine or a pharmacologically acceptable salt thereof. Through research, the present invention finds that the combined use of ivabradine and ranolazine effectively alleviates myocardial ischemia, and shows a good synergistic effect on myocardial ischemia diseases such as angina pectoris and coronary heart disease. Therefore, a method for treating myocardial ischemic diseases with better effect and lower adverse reactions has been found, and a good solution has been found for the unsatisfactory treatment effect of myocardial ischemic diseases in clinical practice.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating myocardial ischemic diseases containing active ingredients ivabradine or a pharmaceutically acceptable salt thereof and ranolazine or a pharmaceutically acceptable salt thereof. Background technique

[0002] The traditional treatment of myocardial ischemic diseases is mainly symptomatic treatment. Nitrates, adrenergic β-receptor blockers, calcium channel antagonists, etc. improve the hemodynamics of the heart and the whole body, increase myocardial energy supply, The purpose of reducing myocardial energy consumption is the main drug for the treatment of myocardial ischemia. However, there are still some patients whose symptoms cannot be well controlled after receiving sufficient above-mentioned drug treatment. With further clinical research and understanding, a new concept of treating ischemic heart disease by intervening in the metabol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More